Clinical Trial Update: Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study assessing dose-response and pharmacokinetics of gabapentin enacarbil for restless legs syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• gabapentin enacarbil (gabapentin enacarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Restless Legs Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2011-05-26